Table 1.
Reference | n | Site | Treatment | Outcome |
---|---|---|---|---|
de Holanda 2007 [37] | 58 | Knee OA | Double-blind, placebo controlled, 4 months, 7.5 mg/week | No statistically significant difference between both groups regarding WOMAC (P = 0.94), Lequèsne Algofunctional Index (P = 0.87) and VAS (P = 0.89. No significant difference in paracetamol consumption between both groups, however, there was tendency to increased consumption in the placebo group. |
Pavelka 2006 [38] | 21 | Erosive hand OA | Open label, 10 mg of MTX orally for two months | Significant decrease of pain after 2 months of treatment (54.4 ± 17.0 mm versus 39.7 ± 19.6 mm, P <0.01) and stiffness (28.8 ± 24 min versus 21.8 ± 19.1 min, P <0.01) |
Chollet-Janin 2007 [39] | 5 | CPPD | Open label, 5 to 20 mg/week | Clinical response in all 5 patients with significant reduction in pain intensity, swollen and tender joint counts and mean improvement time of 7.4 weeks |
CPPD, calcium pyrophosphate deposition disease; MTX, methotrexate; OA, osteoarthritis; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Osteoarthritis Index.